Suppr超能文献

2002 年至 2010 年博茨瓦纳国家艾滋病毒/艾滋病治疗方案的结果:纵向分析。

Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.

机构信息

Harvard School of Public Health, Boston, MA, USA.

Harvard School of Public Health, Boston, MA, USA.

出版信息

Lancet Glob Health. 2014 Jan;2(1):e44-50. doi: 10.1016/S2214-109X(13)70149-9. Epub 2013 Dec 11.

Abstract

BACKGROUND

Short-term mortality rates among patients with HIV receiving antiretroviral therapy (ART) in sub-Saharan Africa are higher than those recorded in high-income countries, but systematic long-term comparisons have not been made because of the scarcity of available data. We analysed the effect of the implementation of Botswana's national ART programme, known as Masa, from 2002 to 2010.

METHODS

The Masa programme started on Jan 21, 2002. Patients who were eligible for ART according to national guidelines had their data collected prospectively through a clinical information system developed by the Botswana Ministry of Health. A dataset of all available electronic records for adults (≥18 years) who had enrolled by April 30, 2010, was extracted and sent to the study team. All data were anonymised before analysis. The primary outcome was mortality. To assess the effect of loss to follow-up, we did a series of sensitivity analyses assuming varying proportions of the population lost to follow-up to be dead.

FINDINGS

We analysed the records of 126,263 patients, of whom 102,713 had documented initiation of ART. Median follow-up time was 35 months (IQR 14-56), with a median of eight follow-up visits (4-14). 15,270 patients were deemed lost to follow-up by the end of the study. 63% (78,866) of the study population were women; median age at baseline was 34 years for women (IQR 29-41) and 38 years for men (33-45). 10,230 (8%) deaths were documented during the 9 years of the study. Mortality was highest during the first 3 months after treatment initiation at 12·8 deaths per 100 person-years (95% CI 12·4-13·2), but decreased to 1·16 deaths per 100 person-years (1·12-1·2) in the second year of treatment, and to 0·15 deaths per 100 person-years (0·09-0·25) over the next 7 years of follow-up. In each calendar year after the start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from 101 cells/μL [IQR 44-156] in 2002, to 191 cells/μL [115-239] in 2010). In each year, the proportion of the total enrolled population who died in that year decreased, from 63% (88 of 140) in 2002, to 0·8% (13 of 1599) in 2010. A sensitivity analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths, increasing overall mortality from 8% to 11-13%.

INTERPRETATION

The Botswana national HIV/AIDS treatment programme reduced mortality among adults with HIV to levels much the same as in other low-income or middle-income countries.

FUNDING

The African Comprehensive HIV/AIDS Partnerships.

摘要

背景

在撒哈拉以南非洲接受抗逆转录病毒疗法(ART)的 HIV 患者的短期死亡率高于高收入国家记录的死亡率,但由于可用数据稀缺,尚未进行系统的长期比较。我们分析了 2002 年至 2010 年博茨瓦纳国家 ART 计划(称为 Masa)实施的效果。

方法

Masa 计划于 2002 年 1 月 21 日开始。根据国家指南符合 ART 条件的患者通过博茨瓦纳卫生部开发的临床信息系统前瞻性地收集数据。提取并发送给研究小组所有在 2010 年 4 月 30 日之前登记的成年人(≥18 岁)的所有可用电子记录数据集。所有数据在分析前均进行了匿名处理。主要结局是死亡率。为评估失访的影响,我们进行了一系列敏感性分析,假设不同比例的人群失访为死亡。

结果

我们分析了 126263 名患者的记录,其中 102713 名患者记录了开始接受 ART。中位随访时间为 35 个月(IQR 14-56),中位数随访 8 次(4-14 次)。到研究结束时,有 15270 名患者被认为失访。研究人群中 63%(78866 人)为女性;女性基线时的中位年龄为 34 岁(IQR 29-41),男性为 38 岁(33-45)。在 9 年的研究期间,记录了 10230 例(8%)死亡。治疗开始后前 3 个月死亡率最高,为每 100 人年 12.8 例死亡(95%CI 12.4-13.2),但在第二年治疗时降至每 100 人年 1.16 例死亡(1.12-1.2),接下来的 7 年随访中降至每 100 人年 0.15 例死亡(0.09-0.25)。自 2002 年 Masa 计划开始以来,每年的平均 CD4 细胞计数都在增加(从 2002 年的 101 个/μL(IQR 44-156)增加到 2010 年的 191 个/μL(115-239))。每年,当年死亡的总登记人口比例均在下降,从 2002 年的 63%(88/140)下降到 2010 年的 0.8%(13/1599)。假设 60%的失访人群死亡的敏感性分析得出,3000 人死亡,使总死亡率从 8%上升至 11-13%。

解释

博茨瓦纳国家 HIV/AIDS 治疗计划将成年人的 HIV 死亡率降低到与其他低收入或中等收入国家相当的水平。

资助

非洲综合艾滋病毒/艾滋病伙伴关系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验